deltatrials
Completed NA NCT02080650

Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)

Sponsor: Duke University

Conditions Advanced MET Amplified Solid Tumor Bladder Cancer Colorectal Cancer Gastric Cancer Non-small Cell Lung Cancer Pancreatic Cancer Prostate Cancer Renal Cell Carcinoma
Interventions Epithelial cell adhesion molecule (EpCAM) ferrofluid Mesenchymal-marker based ferrofluid (c-MET)
Updated 6 times since 2017 Last updated: Jul 31, 2017 Started: Mar 31, 2014 Primary completion: May 19, 2016 Completion: Jul 19, 2016

This NA trial investigates Advanced MET Amplified Solid Tumor and Bladder Cancer and is currently completed. Duke University leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Aug 2017 — Jun 2018 [monthly]

    Completed NA

    Status: Recruiting → Completed

▶ Show 1 earlier version

  1. Jan 2017 — Aug 2017 [monthly]

    Recruiting NA

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Duke University
  • Janssen Diagnostics, LLC
  • Prostate Cancer Foundation
Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Durham, United States